NEU neuren pharmaceuticals limited

MIAMI, Nov. 11, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc....

  1. 726 Posts.
    lightbulb Created with Sketch. 406
    MIAMI, Nov. 11, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced the completion of enrollment and positive preliminary findings from Part 1 of the ongoing HALOS Phase 1/2a study of ION582 (BIIB121) in Angelman syndrome. ION582 was generally well tolerated in the study and showed encouraging electroencephalogram (EEG) activity trends and early signals of positive clinical improvement, which will need to be confirmed upon analysis of the full data set in mid-2024. The findings were presented today at the FAST (Foundation for Angelman Syndrome Therapeutics) Summit; the presentation is available here. Part 1 of the HALOS trial is a three-month, open-label, multiple-ascending dose study. Part 2 is a long-term extension study, which will evaluate ION582 for an additional 12 months.


    https://www.prnewswire.com/news-rel...f-ion582-for-angelman-syndrome-301985239.html
    Last edited by Piton72: 12/11/23
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$13.88
Change
-0.140(1.00%)
Mkt cap ! $1.727B
Open High Low Value Volume
$13.90 $14.21 $13.64 $4.590M 329.8K

Buyers (Bids)

No. Vol. Price($)
1 600 $13.85
 

Sellers (Offers)

Price($) Vol. No.
$13.96 2894 1
View Market Depth
Last trade - 16.10pm 08/07/2025 (20 minute delay) ?
NEU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.